Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-30

Prothena Corp Public LTD (PRTA)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$5,896,045
Gene Kinney total, FY2025
50th
CEO pay percentile vs peers
1:1
CEO-to-median pay ratio
96.58%
Say-on-pay support, latest vote
Companies that benchmark against PRTA
6 companies name PRTA as a compensation peer

Each company listed discloses PRTA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PRTA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Gene Kinney$692,973$0$961,800$3,809,738$415,784$0$15,750$5,896,045
President and Chief Executive Officer
Brandon Smith540,7130893,1001,092,125270,356015,7502,812,044
Chief Operating Officer
Tran Nguyen600,3890652,6501,092,125300,195015,7502,661,109
Chief Strategy Officer and Chief Financial Officer
Chad Swanson516,6670583,9501,092,125206,667015,7502,415,159
Chief Development Officer
Wagner Zago514,2210583,9501,092,125205,689015,7502,411,735
Chief Scientific Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Gene Kinney$5,896,045
Brandon Smith2,812,044
Tran Nguyen2,661,109
Chad Swanson2,415,159
Wagner Zago2,411,735

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Anne Evans KingstonChief Strategy Officer2026-04-10A100,000$0$0Derivative, Class A CommonForm 4 ↗
Lars G. EkmanDirector2026-05-15A27,00000Derivative, Class A CommonForm 4 ↗
Dennis J. SelkoeDirector2026-05-15A27,00000Derivative, Class A CommonForm 4 ↗
Daniel G. WelchDirector2026-05-15A27,00000Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-15A27,00000Derivative, Class A CommonForm 4 ↗
William H. Dunn, JrDirector2026-05-15A27,00000Derivative, Class A CommonForm 4 ↗
Richard T. CollierDirector2026-05-15A27,00000Derivative, Class A CommonForm 4 ↗
William P. ScullyGreater-than-10% holder2026-05-22A100,00010981,300CommonForm 4 ↗
William P. ScullyGreater-than-10% holder2026-06-02A50,0009471,300CommonForm 4 ↗
William P. ScullyGreater-than-10% holder2026-06-04A50,0009465,295CommonForm 4 ↗
William P. ScullyGreater-than-10% holder2026-06-11A125,00081,021,225CommonForm 4 ↗
William P. ScullyGreater-than-10% holder2026-06-15D325,00000CommonForm 4 ↗
William P. ScullyGreater-than-10% holder2026-06-16A20,0008157,990CommonForm 4 ↗
Wagner ZagoChief Scientific Officer2026-07-28A51,000CommonForm 4 ↗
Brandon SmithChief Operating Officer2026-07-28A78,000CommonForm 4 ↗
Gene G. KinneyDirector2026-07-28D84,00000Derivative, Class A CommonForm 4 ↗
Brandon SmithChief Operating Officer2026-07-28D78,0009667,680CommonForm 4 ↗
Chad SwansonChief Development Officer2026-07-28A51,000CommonForm 4 ↗
Karin L. WalkerChief Accounting Officer2026-07-28D15,0009128,400CommonForm 4 ↗
Wagner ZagoChief Scientific Officer2026-07-28D51,00000Derivative, Class A CommonForm 4 ↗
Wagner ZagoChief Scientific Officer2026-07-28D51,0009436,560CommonForm 4 ↗
Karin L. WalkerChief Accounting Officer2026-07-28A15,000CommonForm 4 ↗
Anne Evans KingstonChief Strategy Officer2026-07-28D7,662864,919Common, open-market saleForm 4 ↗
Karin L. WalkerChief Accounting Officer2026-07-28D15,00000Derivative, Class A CommonForm 4 ↗
Gene G. KinneyDirector2026-07-28D84,0009719,040CommonForm 4 ↗
Chad SwansonChief Development Officer2026-07-28D3,467929,678CommonForm 4 ↗
Tran NguyenChief Strategy Officer and CFO2026-07-28D57,00000Derivative, Class A CommonForm 4 ↗
Anne Evans KingstonChief Strategy Officer2026-07-28D3,498929,943CommonForm 4 ↗
Chad SwansonChief Development Officer2026-07-28D40,8009349,248CommonForm 4 ↗
Brandon SmithChief Operating Officer2026-07-28D78,00000Derivative, Class A CommonForm 4 ↗
Tran NguyenChief Strategy Officer and CFO2026-07-28D57,0009487,920CommonForm 4 ↗
Tran NguyenChief Strategy Officer and CFO2026-07-28A57,000CommonForm 4 ↗
Chad SwansonChief Development Officer2026-07-28D51,00000Derivative, Class A CommonForm 4 ↗
Gene G. KinneyDirector2026-07-28A84,000CommonForm 4 ↗
Michael John IsaacsGeneral Counsel & Company Sec.2026-07-28D8,386871,055Common, open-market saleForm 4 ↗
Michael John IsaacsGeneral Counsel & Company Sec.2026-07-28D4,694940,181CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Tran NguyenOPTION2025-03-05107,500$1,092,125
Wagner ZagoOPTION2025-03-05107,5001,092,125
Gene KinneyOPTION2025-03-05375,0003,809,738
Chad SwansonOPTION2025-03-05107,5001,092,125
Brandon SmithOPTION2025-03-05107,5001,092,125
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Tran Nguyen$0$0$1,092,1250.0%
Wagner Zago001,092,1250.0%
Gene Kinney003,809,7380.0%
Chad Swanson001,092,1250.0%
Brandon Smith001,092,1250.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Tran NguyenOption107,50014.95
Brandon SmithOption15,00052.97
Brandon SmithOption107,50014.95
Gene KinneyRSU140,0001,337,000
Brandon SmithRSU130,0001,241,500
Tran NguyenRSU95,000907,250
Chad SwansonOption14,62530.3
Chad SwansonOption107,50014.95
Wagner ZagoOption46,04230.3
Gene KinneyOption166,29230.3
Gene KinneyOption375,00014.95
Tran NguyenOption15,00052.97
Tran NguyenOption3,54232.45
Brandon SmithOption46,04230.3
Wagner ZagoOption15,00052.97
Chad SwansonRSU85,000811,750
Wagner ZagoRSU85,000811,750
Gene KinneyOption10,41732.45
Gene KinneyOption48,43852.97
Chad SwansonOption24,79253.67
Chad SwansonOption28,33416.65
Brandon SmithOption3,54232.45
Tran NguyenOption46,04230.3
Wagner ZagoOption3,54232.45
Wagner ZagoOption107,50014.95
05

Incentive-plan design — the Compensation Discussion & Analysis

The principal objective of our executive compensation programs is to attract, retain, motivate, and reward individuals with the executive experience and skills necessary for us to achieve our ultimate goal of increasing shareholder value. In order to do this, our executive compensation programs are designed to: Attract and retain individuals of superior ability, experience, and management talent; Motivate and reward executives whose knowledge, skills, and performance support our continued success; Align compensation with corporate strategies, business and financial objectives, operational needs, and the long-term interests of our shareholders; Avoid elements of compensation that would encourage excessive risk-taking or otherwise create inappropriate incentives; and Provide total compensation that is fair, reasonable, and competitive relative to both internal and external comparison points.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantPay Governance
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1432,303,0761,145,4001,204,89996.58%Passed
20232023-05-1645,196,711358,6281,184,43699.21%Passed
20222022-05-1741,665,912337,89038,60399.2%Passed
20212021-05-1827,615,0356,734,17922,12580.39%Passed
20202020-05-1932,956,5711,573,03625,86395.44%Passed
20192019-05-2122,460,37710,616,209879,95767.9%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1496.58%a
20232023-05-1699.21%b
20222022-05-1799.2%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)1 : 1
CEO total compensation$5,896,045
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Daniel G. WelchIndependent · Board Chair · Compensation$97,089$0$95,831$0$0$192,920
Shane M. CookeIndependent · Audit (Chair) · Compensation (Chair)87,500095,8310183,331
Paula K. CobbIndependent · Departed during FY85,000095,8310180,831
Lars G. EkmanIndependent · Audit · Research and Development (Chair)80,000095,8310175,831
Richard T. CollierIndependent · Audit · Nominating and Corporate Governance (Chair)80,000095,8310175,831
Dennis J. SelkoeIndependent · Compensation · Research and Development70,000095,83106,500172,331
William H. Dunn, JrIndependent · Nominating and Corporate Governance · Research and Development74,726095,8310170,557
Helen S. KimIndependent · Nominating and Corporate Governance · Not standing for re-election65,000095,8310160,831
Gene G. KinneyEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$60,000
Annual equity retainer$95,831
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)90,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$639,315
Equity awards (grant-date value)$0
All other compensation$6,500
Total cost of the board$645,815

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Prothena Corp Public LTD names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Prothena Corp Public LTD.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Biohaven Ltd.2025Vlad Coric$920,400$2,202,480$9,900,043$0$13,500,438
2Axsome2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
3Intra-Cellular2023Sharon Mates891,6537,749,9840010,086,413
4Arcus Biosciences2025Terry Rosen775,0002,199,4506,008,860658,7509,656,813
5Sage Therapeutics2024Barry Greene830,7123,164,3642,669,263431,9707,112,589
6Prothena Corp Public LTD2025Gene Kinney692,973961,8003,809,738415,7845,896,045
7Replimune Group2026Sushil Patel700,0003,376,0031,448,325315,0005,845,982
8Celldex Therapeutics2025Anthony Marucci785,80404,027,59005,366,709
9Denali Therapeutics2025Ryan Watts718,0001,151,8672,180,00304,751,515
10Neumora Therapeutics2025Paul Berns700,00003,326,181504,0004,562,461
11Anavex Life Sciences2024Christopher Missling700,00001,927,60002,783,700

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Prothena Corp Public LTD100%not disclosednot disclosedPay Governance
Anavex Life Sciences20%Options 100not disclosednot disclosed
Arcus Biosciences100%Options 67 · RSU 33not disclosedRadford
Axsome150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
Biohaven Ltd.67%not disclosednot disclosedAon Human Capital Solutions
Celldex Therapeutics100%Options 100not disclosedAon (Human Capital Solutions practice, a division of Aon plc)
Denali Therapeutics145%not disclosednot disclosedAlpine Rewards
Intra-Cellular150%RSU 75 · PSU 25Yes — Total Stockholder Return (TSR) relative to Nasdaq Biotechnology IndexAon Consulting, Inc.
Neumora Therapeuticsnot disclosedOptions 100not disclosedAlpine Rewards, LLC
Replimune Groupnot disclosednot disclosedNoPearl Meyer
Sage Therapeutics80%not disclosedYes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology IndexAlpine Rewards

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Gene KinneyDEF 14A2026-03-270001559053-26-000012Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 5,896,045. Filing ↗machine: r3 · c27 · span 627016–627025
2Section 01, Brandon SmithDEF 14A2026-03-270001559053-26-000012Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 2,812,044. Filing ↗machine: r9 · c27 · span 643823–643832
3Section 01, Tran NguyenDEF 14A2026-03-270001559053-26-000012Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 2,661,109. Filing ↗machine: r6 · c27 · span 635385–635394
4Section 01, Chad SwansonDEF 14A2026-03-270001559053-26-000012Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 2,415,159. Filing ↗machine: r12 · c27 · span 652214–652223
5Section 01, Wagner ZagoDEF 14A2026-03-270001559053-26-000012Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 2,411,735. Filing ↗machine: r14 · c27 · span 656280–656289
6Section 03, Tran Nguyen OPTIONDEF 14A2026-03-270001559053-26-000012Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t143 · r6 · c9 · span 634159–634168
7Section 03, Wagner Zago OPTIONDEF 14A2026-03-270001559053-26-000012Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t147 · r16 · c19 · span 704580–704589
8Section 03, Gene Kinney OPTIONDEF 14A2026-03-270001559053-26-000012Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t147 · r4 · c13 · span 677262–677269
9Section 03, Chad Swanson OPTIONDEF 14A2026-03-270001559053-26-000012Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t147 · r13 · c19 · span 697872–697881
10Section 03, Brandon Smith OPTIONDEF 14A2026-03-270001559053-26-000012Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t143 · r9 · c9 · span 642572–642581
11Section 07, pay ratioDEF 14A2026-03-270001559053-26-000012Section “CEO Pay Ratio”. As printed: 1 : 1. Filing ↗machine: t13 · r0 · c0 · span 110592–110593
12Section 08, Daniel G. WelchDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 192,920. Filing ↗machine: t83 · r9 · c10 · span 359189–359196
13Section 08, Shane M. CookeDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 183,331. Filing ↗machine: t83 · r4 · c11 · span 349515–349522
14Section 08, Paula K. CobbDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 180,831. Filing ↗machine: t83 · r2 · c11 · span 345700–345707
15Section 08, Lars G. EkmanDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 175,831. Filing ↗machine: t83 · r6 · c11 · span 353371–353378
16Section 08, Richard T. CollierDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 175,831. Filing ↗machine: t83 · r3 · c11 · span 347595–347602
17Section 08, Dennis J. SelkoeDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 172,331. Filing ↗machine: t83 · r8 · c11 · span 357220–357227
18Section 08, William H. Dunn, JrDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 170,557. Filing ↗machine: t83 · r5 · c11 · span 351452–351459
19Section 08, Helen S. KimDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 160,831. Filing ↗machine: t83 · r7 · c11 · span 355300–355307
20Section 08, Gene G. KinneyDEF 14A2026-03-270001559053-26-000012Section “Director Compensation”. As printed: 0. Filing ↗
21Section 02, Anne Evans Kingston 2026-04-10Form 42026-04-100000905148-26-001653Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Lars G. Ekman 2026-05-15Form 42026-05-150000905148-26-002469Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Dennis J. Selkoe 2026-05-15Form 42026-05-150000905148-26-002470Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Daniel G. Welch 2026-05-15Form 42026-05-150000905148-26-002471Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Shane M. Cooke 2026-05-15Form 42026-05-150000905148-26-002467Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, William H. Dunn, Jr 2026-05-15Form 42026-05-150000905148-26-002468Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Richard T. Collier 2026-05-15Form 42026-05-150000905148-26-002466Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, William P. Scully 2026-05-22Form 42026-05-260001045463-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, William P. Scully 2026-06-02Form 42026-06-030001045463-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, William P. Scully 2026-06-04Form 42026-06-050001045463-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, William P. Scully 2026-06-11Form 42026-06-120001045463-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, William P. Scully 2026-06-15Form 42026-06-160001045463-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, William P. Scully 2026-06-16Form 42026-06-180001045463-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Wagner Zago 2026-07-28Form 42026-07-300000905148-26-003417Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Brandon Smith 2026-07-28Form 42026-07-300000905148-26-003414Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Gene G. Kinney 2026-07-28Form 42026-07-300000905148-26-003412Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Brandon Smith 2026-07-28Form 42026-07-300000905148-26-003414Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Chad Swanson 2026-07-28Form 42026-07-300000905148-26-003415Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Karin L. Walker 2026-07-28Form 42026-07-300000905148-26-003416Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Wagner Zago 2026-07-28Form 42026-07-300000905148-26-003417Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Wagner Zago 2026-07-28Form 42026-07-300000905148-26-003417Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Karin L. Walker 2026-07-28Form 42026-07-300000905148-26-003416Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Anne Evans Kingston 2026-07-28Form 42026-07-300000905148-26-003410Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Karin L. Walker 2026-07-28Form 42026-07-300000905148-26-003416Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Gene G. Kinney 2026-07-28Form 42026-07-300000905148-26-003412Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Chad Swanson 2026-07-28Form 42026-07-300000905148-26-003415Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Tran Nguyen 2026-07-28Form 42026-07-300000905148-26-003413Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Anne Evans Kingston 2026-07-28Form 42026-07-300000905148-26-003410Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Chad Swanson 2026-07-28Form 42026-07-300000905148-26-003415Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Brandon Smith 2026-07-28Form 42026-07-300000905148-26-003414Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Tran Nguyen 2026-07-28Form 42026-07-300000905148-26-003413Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Tran Nguyen 2026-07-28Form 42026-07-300000905148-26-003413Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Chad Swanson 2026-07-28Form 42026-07-300000905148-26-003415Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Gene G. Kinney 2026-07-28Form 42026-07-300000905148-26-003412Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Michael John Isaacs 2026-07-28Form 42026-07-300000905148-26-003409Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Michael John Isaacs 2026-07-28Form 42026-07-300000905148-26-003409Insider equity transaction reported since the proxy statement. Filing ↗
57Section 06, 2026 voteForm 8-K2026-05-150001193125-26-226968Item 5.07 · say-on-pay result. As reported: 96.58% (votes for as printed: 32,303,076). Filing ↗
58Section 06, 2023 voteForm 8-K2023-05-190001193125-23-149386Item 5.07 · say-on-pay result. As reported: 99.21% (votes for as printed: 45,196,711). Filing ↗
59Section 06, 2022 voteForm 8-K2022-05-200001559053-22-000026Item 5.07 · say-on-pay result. As reported: 99.2%. Filing ↗
60Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
61Section 09b board cost (computed)ComputedcomputedCash 639,315 + equity 0 + all other 6,500 = 645,815, summed across the director compensation table rows.machine: formula: Σ = 645,815
62Biohaven Ltd., Section 10b CEO totalDEF 14A2026-03-130001935979-26-000028CEO total compensation as printed in Biohaven Ltd.'s own proxy. As printed: 13,500,438. Filing ↗machine: t25 · r3 · c7 · span 423429–423439
63Axsome, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
64Intra-Cellular, Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
65Arcus Biosciences, Section 10b CEO totalDEF 14A2026-04-210001724521-26-000025CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749
66Sage Therapeutics, Section 10b CEO totalDEF 14A2025-04-240000950170-25-058060CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793
67Prothena Corp Public LTD (subject), Section 10b CEO totalDEF 14A2026-03-270001559053-26-000012CEO total compensation as printed in Prothena Corp Public LTD's own proxy. As printed: 5,896,045. Filing ↗machine: r3 · c27 · span 627016–627025
68Replimune Group, Section 10b CEO totalDEF 14A2026-07-290001104659-26-087650CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774
69Celldex Therapeutics, Section 10b CEO totalDEF 14A2026-04-290001104659-26-050884CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866
70Denali Therapeutics, Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614
71Neumora Therapeutics, Section 10b CEO totalDEF 14A2026-04-170001193125-26-161489CEO total compensation as printed in Neumora Therapeutics's own proxy. As printed: 4,562,461. Filing ↗machine: r2 · c29 · span 444810–444819
72Anavex Life Sciences, Section 10b CEO totalDEF 14A2025-04-250001731122-25-000607CEO total compensation as printed in Anavex Life Sciences's own proxy. As printed: 2,783,700. Filing ↗machine: r1 · c23 · span 229348–229357
73Section 10a, Intra-Cellular reciprocityDEF 14A0001628280-24-018986Intra-Cellular's most recent proxy was read; its disclosed peer group does not include Prothena Corp Public LTD. Filing ↗
74Section 10a, Celldex Therapeutics reciprocityDEF 14A0001104659-26-050884Celldex Therapeutics's most recent proxy was read; its disclosed peer group does not include Prothena Corp Public LTD. Filing ↗
75Section 10a, Biohaven Ltd. reciprocityDEF 14A0001935979-26-000028Biohaven Ltd.'s most recent proxy was read; its disclosed peer group does not include Prothena Corp Public LTD. Filing ↗
76Section 10a, Denali Therapeutics reciprocityDEF 14A0001714899-26-000054Denali Therapeutics names Prothena Corp Public LTD in its own disclosed peer group (read from its most recent proxy). Filing ↗
77Section 10a, Axsome reciprocityDEF 14A0001193125-26-177610Axsome's most recent proxy was read; its disclosed peer group does not include Prothena Corp Public LTD. Filing ↗
78Section 10a, Sage Therapeutics reciprocityDEF 14A0000950170-25-058060Sage Therapeutics's most recent proxy was read; its disclosed peer group does not include Prothena Corp Public LTD. Filing ↗